<DOC>
	<DOCNO>NCT02284906</DOCNO>
	<brief_summary>The purpose study evaluate effect pioglitazone 24 month compare placebo cognitive decline high-risk participant complete AD-4833/TOMM40_301 study [ NCT01931566 ] adjudicate diagnosis mild cognitive impairment ( MCI ) due Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>AD-4833/TOMM40_303 Extension Study Safety Efficacy Pioglitazone Slow Cognitive Decline Participants With Mild Cognitive Impairment Due Alzheimer Disease</brief_title>
	<detailed_description>The drug test study call pioglitazone . This study design evaluate safety effectiveness pioglitazone cognitive function participant complete AD-4833/TOMM40_301 . This study look effectiveness pioglitazone cognitive decline high-risk participant complete AD-4833/TOMM40_301 study diagnosis mild cognitive impairment ( MCI ) due Alzheimer 's Disease ( AD ) . The study anticipate enroll approximately 316 participant , dependent many decide continue treatment extension phase complete main ( 301 ) study . Participants continue receive study medication receive pivotal AD-4833/TOMM40_301 study , either : - pioglitazone 0.8 mg tablet - placebo ( tablet look like study drug active ingredient ) . All participant ask take one tablet time day throughout study . This multi-centre trial , like precedent pivotal trial , conduct worldwide . The overall time participate study minimum 2 year maximum 7 year depend subject roll 301 study . Participants make approximately 2 visit per year clinic , contact telephone 3 month treatment visit follow-up assessment , 2 week final visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Completed pivotal AD4833/TOMM40_301 study adjudicate diagnosis mild cognitive impairment ( MCI ) due Alzheimer 's Disease ( AD ) without ongoing serious adverse event ( SAEs ) AD4833/TOMM40_301 . 2 . Is male female least 65 year age time Baseline Visit . 3 . In opinion investigator , capable understand comply protocol requirement . 4 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 5 . Must live independently nonmedical residential care . 6 . Has project partner able separately consent his/her behalf take part study ( intent long participant enrol ) , provide information cognitive , functional , behavioral status participant assist observation adverse event ( AEs ) monitoring study medication , need . Project partner participate pivotal AD4833/TOMM40_301 study encourage participate extension study capacity . 1 . Completed pivotal AD4833/TOMM40_301 study adjudicate diagnosis AD dementia . 2 . Has current diagnosis significant psychiatric illness , per Diagnostic Statistical Manual Mental Disorders , 4th Edition ( include limited major depressive disorder , anxiety disorder ) acute phase/episode , participant current diagnosis history schizophrenia bipolar disorder . 3 . Has glycosylated hemoglobin ( HbA1c ) &gt; 8 % extension study Baseline Visit require treatment insulin , triple oral antidiabetic therapy peroxisome proliferatoractivated receptor gamma ( PPARÎ³ ) agonist . 4 . Has clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal ( include s/p gastric bypass surgery ) , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . 5 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , pivotal , child , sibling ) may consent duress . 6 . Is required take exclude medication . 7 . Has history hypersensitivity allergies pioglitazone related compound . 8 . Had follow value extension study Baseline Visit : 1 . A serum total bilirubin value &gt; 15 x upper limit normal ( ULN ) . 2 . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 x ULN . 3 . Unexplained microscopic/macroscopic hematuria 2 repeat examination within 2 week . 9 . Has disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy , prevent participant adequately participate study continue anticipate duration study . 10 . Has receive investigational compound , exception treatment AD4833/TOMM40_301 study , within 30 day prior Baseline 5 halflives prior Baseline currently participate another study entail administration investigational marketed drug , supplement , intervention include , limited diet , exercise , lifestyle , invasive procedure . 11 . Has cancer remission le 2 year extension study Baseline Visit . Participants basal cell stage I squamous cell carcinoma skin eligible . Participants current diagnosis bladder cancer eligible irrespective remission status . 12 . Has current diagnosis macular edema , degeneration maculopathy . 13 . Has history current diagnosis congestive heart failure ( CHF ) , New York Heart Association class IIIIV .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>